Bioxyne Ltd
BXN
Company Profile
Business description
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments namely, wholesale sales, Plant-based, Manufacturing sales, and direct sales. The majority of the revenue is generated from plants based segment.
Contact
50 Clarence Street
Suite 506, Level 5
SydneyNSW2000
AUST: +61 290787669
Sector
Consumer Defensive
Stock type
Defensive
Industry
Packaged Foods
Fiscal Year End
30 June 2025
Employees
16
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
Current operating conditions are challenging but over the long-term prospects are better.
stocks
Why Guzman and Reece's share reversals have a lot in common
Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,477.30 | 20.70 | -0.24% |
| CAC 40 | 8,141.19 | 90.12 | 1.12% |
| DAX 40 | 22,790.56 | 380.29 | 1.70% |
| Dow JONES (US) | 43,810.49 | 189.33 | 0.43% |
| FTSE 100 | 8,732.37 | 63.70 | 0.73% |
| HKSE | 23,787.93 | 753.91 | 3.27% |
| NASDAQ | 19,269.50 | 243.11 | 1.28% |
| Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
| NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
| S&P 500 | 6,007.46 | 52.21 | 0.88% |
| S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
| SSE Composite Index | 3,380.21 | 34.17 | 1.02% |